Literature DB >> 31221807

King's Brief Interstitial Lung Disease questionnaire: responsiveness and minimum clinically important difference.

Claire M Nolan1,2, Surinder S Birring3, Matthew Maddocks4, Toby M Maher5,6, Suhani Patel7, Ruth E Barker7,5, Sarah E Jones7,5, Jessica A Walsh7,2, Stephanie C Wynne7, Peter M George5,6, William D-C Man7,2,5.   

Abstract

Health status is increasingly used in clinical practice to quantify symptom burden and as a clinical trial end-point in patients with interstitial lung disease (ILD). The King's Brief Interstitial Lung Disease (KBILD) questionnaire is a brief, validated 15-item, disease-specific, health-related quality of life questionnaire that is increasingly used in clinical trials, but little data exist regarding the minimum clinically important difference (MCID). Using pulmonary rehabilitation as a model, we aimed to determine the responsiveness of KBILD and provide estimates of the MCID.KBILD scores, Chronic Respiratory Questionnaire (CRQ) scores, Medical Research Council (MRC) Dyspnoea score and incremental shuttle walk test (ISWT) distance were measured in 209 patients with ILD (105 with idiopathic pulmonary fibrosis (IPF)) before and after an outpatient pulmonary rehabilitation programme. Changes with intervention and Cohen's effect size were calculated. Anchor-based (linear regression and receiver operating characteristic plots) or distribution-based approaches (0.5 sd and standard error of measurement) were used to estimate the MCID of KBILD domain and total scores.KBILD, CRQ, MRC Dyspnoea and ISWT improved with intervention, and the effect sizes of KBILD domain and total scores ranged from 0.28 to 0.38. Using anchor-based estimates, the MCID estimates for KBILD-Psychological, KBILD-Breathlessness and activities, and KBILD-Total were 5.4, 4.4 and 3.9 points, respectively. Using distribution-based methods, the MCID estimate for KBILD-Chest symptoms was 9.8 points. The MCID estimates for KBILD in IPF patients were similar.In patients with ILD and IPF, KBILD is responsive to intervention with an estimated MCID of 3.9 points for the total score.
Copyright ©ERS 2019.

Entities:  

Mesh:

Year:  2019        PMID: 31221807     DOI: 10.1183/13993003.00281-2019

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  9 in total

1.  The psychometric properties of the King's Brief Interstitial Lung Disease questionnaire and thresholds for meaningful treatment response in patients with progressive fibrosing interstitial lung diseases.

Authors:  Surinder S Birring; Donald M Bushnell; Michael Baldwin; Heiko Mueller; Natalia Male; Klaus B Rohr; Yoshikazu Inoue
Journal:  Eur Respir J       Date:  2022-06-02       Impact factor: 33.795

2.  Home Oxygen Therapy for Adults with Chronic Lung Disease. An Official American Thoracic Society Clinical Practice Guideline.

Authors:  Susan S Jacobs; Jerry A Krishnan; David J Lederer; Marya Ghazipura; Tanzib Hossain; Ai-Yui M Tan; Brian Carlin; M Bradley Drummond; Magnus Ekström; Chris Garvey; Bridget A Graney; Beverly Jackson; Thomas Kallstrom; Shandra L Knight; Kathleen Lindell; Valentin Prieto-Centurion; Elisabetta A Renzoni; Christopher J Ryerson; Ann Schneidman; Jeffrey Swigris; Dona Upson; Anne E Holland
Journal:  Am J Respir Crit Care Med       Date:  2020-11-15       Impact factor: 21.405

3.  Effect of home-based pulmonary rehabilitation on functional capacity in people with idiopathic pulmonary fibrosis-a systematic review protocol.

Authors:  Revati Amin; K Vaishali; G Arun Maiya; Aswini Kumar Mohapatra; Uday Narayan Yadav; Shradha S Parsekar
Journal:  Syst Rev       Date:  2021-11-15

4.  PAciFy Cough-a multicentre, double-blind, placebo-controlled, crossover trial of morphine sulphate for the treatment of pulmonary Fibrosis Cough.

Authors:  Zhe Wu; Winston Banya; Nazia Chaudhuri; Ira Jakupovic; Toby M Maher; Brijesh Patel; Lisa G Spencer; Muhunthan Thillai; Alex West; John Westoby; Marlies Wijsenbeek; Jaclyn Smith; Philip L Molyneaux
Journal:  Trials       Date:  2022-03-02       Impact factor: 2.279

5.  A systematic review on the economic burden of interstitial lung disease and the cost-effectiveness of current therapies.

Authors:  Alyson W Wong; John Koo; Christopher J Ryerson; Mohsen Sadatsafavi; Wenjia Chen
Journal:  BMC Pulm Med       Date:  2022-04-20       Impact factor: 3.320

6.  Rationale and design of the SARCoidosis Outcomes in all respiratory Viral Infectious Diseases (SARCOVID) Study.

Authors:  Rachel Strykowski; Divya C Patel; Manny Ribeiro Neto; Kerry M Hena; Mridu Gulati; LIsa A Maier; Karen Patterson
Journal:  BMJ Open Respir Res       Date:  2022-07

7.  Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease.

Authors:  Tao Chen; Amy Po Yu Tsai; Seo Am Hur; Alyson W Wong; Mohsen Sadatsafavi; Jolene H Fisher; Kerri A Johannson; Deborah Assayag; Julie Morisset; Shane Shapera; Nasreen Khalil; Charlene D Fell; Helene Manganas; Gerard Cox; Teresa To; Andrea S Gershon; Nathan Hambly; Andrew J Halayko; Pearce G Wilcox; Martin Kolb; Christopher J Ryerson
Journal:  Respir Res       Date:  2021-07-08

8.  Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis and COPD: A Propensity-Matched Real-World Study.

Authors:  Claire M Nolan; Oliver Polgar; Susie J Schofield; Suhani Patel; Ruth E Barker; Jessica A Walsh; Karen A Ingram; Peter M George; Philip L Molyneaux; Toby M Maher; William D-C Man
Journal:  Chest       Date:  2021-10-23       Impact factor: 9.410

Review 9.  Minimal clinically important difference in idiopathic pulmonary fibrosis.

Authors:  Mohleen Kang; Lucian Marts; Jordan A Kempker; Srihari Veeraraghavan
Journal:  Breathe (Sheff)       Date:  2021-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.